Based on the US Physicalrapy Inc stock forecast from 2 analysts, the average analyst target price for US Physicalrapy Inc is USD 113.80 over the next 12 months. US Physicalrapy Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of US Physicalrapy Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, US Physicalrapy Inc’s stock price was USD 98.12. US Physicalrapy Inc’s stock price has changed by -5.79% over the past week, -8.03% over the past month and -5.03% over the last year.
No recent analyst target price found for US Physicalrapy Inc
No recent average analyst rating found for US Physicalrapy Inc
Company Overview US Physicalrapy Inc
U.S. Physical Therapy, Inc. operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. It offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. U.S. Physical Therapy, Inc. was founded in 1990 and is based in Houston, Texas. Read Less
U.S. Physical Therapy, Inc. operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, ...Read More
Frequently Asked Questions About US Physicalrapy Inc (USPH) Stock
Based on ratings from 2 analysts US Physicalrapy Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 5 buy, sell and hold ratings.
USPH stock's dividend yield is 1.59%.
Our analysis grades USPH stock's dividend yield at D. This means that USPH stock's dividend yield is above 63% of the stocks in the Medical Care Facilities sector in the NYE exchange.
Based on this USPH may be a average dividend stock for its sector.
Based on targets from 2 analysts, the average taret price for USPH is USD 113.80 over the next 12 months. The maximum analyst target price is USD 122 while the minimum anlayst target price is USD 99.
USPH stock's Price/Earning ratio is 83.15.
Our analysis grades USPH stock's Price / Earning ratio at F. This means that USPH stock's Price/Earning ratio is above 95% of the stocks in the Medical Care Facilities sector in the NYE exchange.
Based on this USPH may be a overvalued for its sector.
The last closing price of USPH's stock was USD 98.12.
The most recent market capitalization for USPH is USD 1.60B.
Based on targets from 2 analysts, the average taret price for USPH is projected at USD 113.80 over the next 12 months.
This means that USPH's stock price may go up by +15.98% over the next 12 months.
Following are ETFs with the highest allocation to US Physicalrapy Inc's stock :
As per our most recent records US Physicalrapy Inc has 3,899 Employees.
US Physicalrapy Inc's registered address is 1300 West Sam Houston Parkway South, Houston, TX, United States, 77042.
You can get more information about it from US Physicalrapy Inc's website at https://www.usph.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for USPH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
